Home
Resources
Publications
New Developments in the Treatment of Opioid-Induced Gastrointestinal Symptoms

New Developments in the Treatment of Opioid-Induced Gastrointestinal Symptoms

Jasper Pannemans, Tim Vanuytsel, Jan Tack

United European Gastroenterol J. 2018 Oct;6(8):1126-1135.

PMID: 30288274

Abstract:

Chronic pain affects a large part of the global population, leading to an increase of opioid use. Opioid-induced constipation (OIC), a highly prevalent adverse effect of opioid use, has a major impact on patients' quality of life. Thanks to the introduction of new drugs for chronic constipation, which can also be used in OIC, and the development of peripherally acting mu-opioid receptor blockers, specifically for use in OIC, therapeutic options have seen major development. This review summarises current and emerging treatment options for OIC based on an extensive bibliographical search. Efficacy data for laxatives, lubiprostone, prucalopride, linaclotide, oxycodone/naloxone combinations, methylnaltrexone, alvimopan, naloxegol, naldemedine, axelopran, and bevenopran in OIC are summarised.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP156053893	Alvimopan		156053-89-3	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: